Experimental device and method for adjusting FTO based on GLP-1

Abstract

The invention discloses a GLP-1-based FTO adjustment experiment device, which comprises two pieces of I-shaped steel, the upper ends of the two pieces of I-shaped steel are fixedly provided with a first fixing frame, a second fixing frame and a third fixing frame at equal intervals, and the first fixing frame is provided with a filter box; the method for adjusting the FTO experimental device based on the GLP-1 comprises the following steps: selecting 6-8-week-old mice, feeding the mice with high-fat diet for 12 weeks, establishing an atherosclerosis model, obtaining required animal tissues after the mice are killed, and carrying out subsequent experiments. The specific mechanism that GLP-1 regulates demethylase FTO to change the m6A methylation level of a differential gene so as to delay the atherosclerosis progress is deeply explored, an epigenetic regulation mechanism in the occurrence and development process of cardiovascular diseases is revealed, and a new theoretical basis is provided for research of the cardiovascular diseases; the field and thought of cardiovascular disease research are expanded, a new theoretical basis is provided for prevention and treatment of cardiovascular diseases, and the morbidity and mortality of the cardiovascular diseases can be reduced.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of cardiovascular disease research, and particularly relates to a GLP-1-based FTO experimental device and method. BACKGROUND

[0002] Cardiovascular disease has long been the leading cause of death and disability worldwide, causing heavy burden to society and family. Among them, atherosclerosis, as the pathological basis of many cardiovascular diseases, has a very complex pathogenesis. It mainly manifests as continuous deposition of cholesterol on the arterial wall, massive accumulation of extracellular matrix and lipids, and abnormal proliferation of smooth muscle cells. In this process, a series of pathological changes such as macrophage infiltration, endothelial dysfunction and plaque formation are intertwined, which can easily lead to acute cardiovascular events such as myocardial infarction and stroke, seriously threatening human life and health.

[0003] In recent years, with the continuous deepening of medical research, the important role of epigenetic mechanisms in pathological cardiovascular events has gradually been recognized. Among them, the RNA methylation molecular mechanism has become one of the research hotspots. RNA methylation modification can regulate the expression and function of genes, and then affect the physiological and pathological processes of cells. In the occurrence and development of atherosclerosis, RNA methylation may be involved in cell proliferation, apoptosis, inflammatory response and other aspects, but the specific mechanism still needs to be further clarified GLP-1 (glucagon-like peptide-1) is a new type of hypoglycemic drug, which was initially concerned because of its significant hypoglycemic effect. However, more and more studies have found that GLP-1 has a positive impact on the cardiovascular system while lowering blood sugar. Previous studies have shown that GLP-1 may affect the occurrence and development of atherosclerosis through multiple pathways, such as protecting vascular endothelial cells from damage, inhibiting vascular inflammatory response and stabilizing atherosclerotic plaques. However, the specific molecular mechanisms of these effects are not yet fully understood, therefore, in-depth study of the mechanism of GLP-1 regulating atherosclerosis has important clinical significance and scientific value, for this reason, we propose a GLP-1-based FTO experimental device and method to solve the above problems. SUMMARY

[0004] The present application aims at solving the problems existing in the prior art, and provides a GLP-1-based FTO experimental device and method.

[0005] In order to achieve the above-mentioned purpose, the present application adopts the following technical scheme: The application discloses a GLP-1 regulating FTO experimental device, which comprises two channel steels, a first fixing frame, a second fixing frame and a third fixing frame are fixed at equal intervals at the upper ends of the two channel steels, a filtering box is installed on the first fixing frame, a protection box is fixed on one side of the filtering box, a pushing mechanism is arranged in the protection box, a collecting barrel is fixed in the filtering box, a filtering barrel is arranged in the collecting barrel, the pushing mechanism is connected with the filtering barrel, a stirring device is installed at the upper end of the first fixing frame and corresponds to the filtering barrel, a rotating device is installed on the third fixing frame, a circular truncated cone bearing barrel is installed on the rotating device, and a grinding device is installed at the upper end of the second fixing frame.

[0006] Preferably, the pushing mechanism comprises a mounting seat fixed on one side in the protection box, a third driving motor is installed on the mounting seat, a rotating rod is connected to the output shaft of the third driving motor, a pull rod is rotatably connected to one end of the rotating rod, a moving block is rotatably connected to one end of the pull rod, the moving block is slidably connected to a guide rail at the lower end, the guide rail is fixed to the bottom of the protection box, the pull rod is fixed to one side of the moving block, and one end of the pull rod penetrates through the side wall of the protection box and the collecting barrel and is rotatably connected to one side of the filtering barrel.

[0007] Preferably, the other side of the filtering barrel is fixed with a fixed plate, two springs are connected to one side of the fixed plate, one end of the spring abuts against one side in the collecting barrel, a guide rod is fixed to one side of the fixed plate, and one end of the guide rod penetrates through the collecting barrel and extends to one side of the collecting barrel.

[0008] Preferably, one side of the collecting barrel is hingedly connected with a connecting cover, one side of the filtering box is hingedly connected with a first sealing cover, and the first sealing cover corresponds to the connecting cover.

[0009] Preferably, the stirring device comprises a first driving motor fixed to the upper end of the first fixing frame, a stirring rod is connected to the output shaft of the first driving motor, the lower end of the stirring rod extends into the filtering barrel, and a plurality of rectangular stirring blades and spiral stirring blades are fixed at equal intervals on the stirring rod.

[0010] Preferably, the rotating device comprises a second driving motor fixed to the upper end of the third fixing frame, a connecting rod is connected to the lower end of the output shaft of the second driving motor, a connecting head is fixed to the lower end of the connecting rod, and the circular truncated cone bearing barrel is screwed to the lower end of the connecting head.

[0011] Preferably, a dispersing box is installed on the third fixing frame, and a third sealing cover is hingedly connected to one side of the dispersing box.

[0012] Preferably, the upper end of the second fixing frame is provided with the grinding device, and a second sealing cover is installed on the grinding device.

[0013] A method for regulating FTO experimental device based on GLP-1, comprising the following steps: S1, animal model establishment, selecting 6-8 week old mice, giving high-fat diet for 12 weeks, establishing an atherosclerosis model; S2, grouping and intervention, high-fat diet group for 16 weeks, GLP-1 group for 12 weeks, GLP-1 for 2.2nmol / (kg·d) intraperitoneal injection for 4 weeks, GLP-1+GLP-1 inhibitor group for 12 weeks, GLP-1 for 2.2nmol / (kg·d)+GLP-1 inhibitor for 22nmol / (kg·d) intraperitoneal injection for 4 weeks; S3, killing mice, taking aortic root tissue, heart, liver and blood, putting the tissue into a filter bucket for treatment, obtaining the required tissue, grinding the grinding device according to the need, and centrifuging the blood according to the need using a rotating device; S4, index detection, aortic root tissue is subjected to oil red O and HE staining, the proportion of plaque area to aortic intima area is analyzed, liver is subjected to oil red O and HE staining, and lipid distribution is observed, animal tissue is ground to extract protein and RNA, Western detection is carried out on the expression of FTO, UCP2 and other related indexes in each group, and PCR is used to determine the FTO and UCP2 mRNA levels in the tissue.

[0014] The operation process of the present application is: 1, experimental device preparation Device structure building: two I-shaped steel are taken as the basis, and a first fixing frame, a second fixing frame and a third fixing frame are fixed on the upper end at equal intervals. A filter box and a stirring device are installed on the first fixing frame, a protection box is arranged on one side of the filter box, and a pushing mechanism is installed inside. A rotating device and a dispersion box are installed on the third fixing frame. A grinding device is installed on the second fixing frame.

[0015] Part installation connection: the filter bucket is placed in the collection bucket and connected with the pushing mechanism through the pull rod; the stirring rod extends into the filter bucket; the connecting head of the rotating device is screwed with the circular table-shaped bearing bucket. At the same time, various covers are installed to facilitate operation and maintenance.

[0016] 2, animal experiment Animal model establishment: 6-8 week old mice are selected, and high-fat diet is given for 12 weeks to establish an atherosclerosis model.

[0017] Grouping and intervention: the mice were divided into high-fat diet group, GLP-1 group and GLP-1+inhibitor group. The high-fat diet group was continuously fed for 16 weeks; the GLP-1 group was fed for 12 weeks, and then GLP-1 2.2 nmol / (kg·d) was injected intraperitoneally for 4 weeks; the GLP-1+GLP-1 inhibitor group was fed for 12 weeks, and then GLP-1 2.2 nmol / (kg·d)+GLP-1 inhibitor 22 nmol / (kg·d) was injected intraperitoneally for 4 weeks.

[0018] Index detection: the mice were sacrificed, and the aortic root tissue, heart, liver and blood were taken. The tissue was placed in a filter bucket for processing, stirred by a stirring device, and moved by a pushing mechanism to complete filtering and other operations. According to the needs, the tissue was ground using a grinding device, and the blood was centrifuged using a rotating device. Then, the aortic root tissue and liver were stained with oil red O and HE, and the plaque area and lipid distribution were analyzed. After the animal tissue was ground, the protein and RNA were extracted, the expression levels of FTO, UCP2 and other related indexes in each group were detected by Western, and the FTO, UCP2 mRNA levels in the tissue were determined by PCR.

[0019] 3. Cell experiment Preparation before experiment: HCAEC (human coronary artery endothelial cells) and ECM endothelial cell culture medium were purchased, and HCAEC was stimulated by 0.1 mg / L LPS to establish an in vitro endothelial cell inflammatory injury model.

[0020] Experimental grouping and intervention: the cells were divided into blank control group (HCAEC+LPS), different concentrations of GLP-1 intervention group (0.5; 1.5; 3; 5; 10 nmol / l) and GLP-1+inhibitor group (the specific concentration was determined according to the results of the pre-experiment).

[0021] Index detection: PCR was used to determine the FTO, UCP2 mRNA levels in each group of cells, Western was used to determine the expression levels of FTO, UCP2 and other related indexes in each group of cells, ELISA was used to measure the contents of IL-1, CRP and ICAM-1 in the supernatant, and the mRNA m6A quantitative detection kit was used for detection.

[0022] The present application has the following advantages: 1. By combining animal experiments and cell experiments, the specific mechanism of GLP-1 regulating the change of the m6A methylation level of the differential gene UCP2 by the demethylase FTO to delay the progression of atherosclerosis is explored in depth, which helps to reveal the epigenetic regulation mechanism in the occurrence and development of cardiovascular diseases, and provides a new theoretical basis for the research of cardiovascular diseases; 2. Combining epigenetics with the study of atherosclerosis expands the field and approach of cardiovascular disease research, and interdisciplinary research methods help to discover new research targets and biomarkers, promoting the development of cardiovascular disease research; 3. The specific mechanism of GLP-1 bringing positive effects on cardiovascular system is clear, which provides new targets and strategies for the treatment of atherosclerosis; 4. It can provide reference for clinicians in using GLP-1 drugs to treat diabetes and cardiovascular disease, guide rational drug use, and improve the safety and effectiveness of drug treatment; 5. It provides a new theoretical basis for the prevention and treatment of cardiovascular disease, which helps to reduce the incidence and mortality of cardiovascular disease and improve the health level of the public; In summary, the present application further explores the specific mechanism of GLP-1 regulating demethylase FTO to change the m6A methylation level of differential genes and delay the progression of atherosclerosis, which helps to reveal the epigenetic regulation mechanism in the development of cardiovascular disease, provides a new theoretical basis for the research of cardiovascular disease, expands the field and approach of cardiovascular disease research, and provides a new theoretical basis for the prevention and treatment of cardiovascular disease, which helps to reduce the incidence and mortality of cardiovascular disease. BRIEF DESCRIPTION OF DRAWINGS

[0023] Figure 1 The structure diagram of the processing device of the present application is shown in the figure; Figure 2 The installation structure diagram of the filter barrel of the present application is shown in the figure; Figure 3 The installation structure diagram of the collection barrel and the filter barrel of the present application is shown in the figure; Figure 4 The structure diagram of the stirring rod of the present application is shown in the figure; Figure 5 The structure diagram of the circular truncated cone bearing barrel of the present application is shown in the figure; Figure 6 The structure diagram of the collection barrel of the present application is shown in the figure; Figure 7 The internal structure diagram of the protection box of the present application is shown in the figure; Figure 8 The flow chart of animal experiment of the present application is shown in the figure; Figure 9 The flow chart of cell experiment of the present application is shown in the figure; Figure 10 The pathological observation result diagram of HE and oil red O staining of the aortic root of each group of mice of the present application is shown in the figure; Figure 11 The expression diagram of vascular endothelial cell CD36 and ACAT1 of the aortic root of each group of mice of the present application is shown in the figure; Figure 12Fig. 1 is a diagram of the protein expression of CD36 (A) and ACAT1 (B) of different concentrations of GLP-1 intervention groups of the present application; Figure 13 Fig. 2 is a diagram of the relative protein expression of CD36 (A) and ACAT1 (B) of each group of cells of the present application; Figure 14 Fig. 3 is an expression diagram of CD36 and ACAT1 antibody fluorescence staining of each group of cells of the present application.

[0024] In the figure: 1 first driving motor, 2 first cover, 3 first fixed frame, 4 protection box, 5 I-beam, 6 grinding device, 7 second fixed frame, 8 second cover, 9 second driving motor, 10 third cover, 11 third fixed frame, 12 stirring rod, 13 rectangular stirring blade, 14 spiral stirring blade, 15 filter barrel, 16 pull rod, 17 collection barrel, 18 guide rod, 19 connecting cover, 20 fixed plate, 21 spring, 22 connecting rod, 23 connecting head, 24 circular truncated cone bearing barrel, 25 third driving motor, 26 mounting seat, 27 rotating rod, 28 pull rod, 29 guide rail, 30 moving block. DETAILED DESCRIPTION

[0025] The technical solutions in the embodiments of the present application will be clearly and completely described below with reference to the drawings in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all the embodiments.

[0026] Reference Figures 1-7 A GLP-1 based FTO experimental device, comprising two I-beams 5, first, second and third fixed frames 3, 7 and 11 are fixed at equal intervals at the upper ends of the two I-beams 5, a filter box is installed on the first fixed frame 3, a protection box 4 is fixed on one side of the filter box 4, a pushing mechanism is arranged in the protection box 4, a collection barrel 17 is fixed in the filter box, a filter barrel 15 is arranged in the collection barrel 17, the pushing mechanism is connected with the filter barrel 15, a stirring device is installed on the upper end of the first fixed frame 3, the stirring device corresponds to the filter barrel 15, a rotating device is installed on the third fixed frame 11, a circular truncated cone bearing barrel 24 is installed on the rotating device, a grinding device 6 is installed on the upper end of the second fixed frame 7, which facilitates centrifugal separation, filtration and grinding operation of animal tissues required for experiments; The pushing mechanism comprises a mounting seat 26 fixed on one side in the protection box 4, a third driving motor 25 mounted on the mounting seat 26, a rotating rod 27 connected at the output shaft end of the third driving motor 25, a pull rod 28 rotatably connected at one end of the rotating rod 27, a moving block 30 rotatably connected at one end of the pull rod 28, the moving block 30 being slidably connected at the lower end to a guide rail 29 fixed at the bottom in the protection box 4, the pull rod 16 being fixed at one side of the moving block 30, one end of the pull rod 16 penetrating through the side wall of the protection box 4 and the collecting barrel 17 and being rotatably connected at one side of the filtering barrel 15, the pushing mechanism being used for driving the filtering barrel 15 to move, so as to realize filtering and other operations; when the third driving motor 25 is started, the rotating rod 27 rotates, the moving block 30 is driven to slide on the guide rail 29 through the pull rod 28, and the filtering barrel 15 is driven to move through the pull rod 16; The other side of the filtering barrel 15 is fixed with a fixed plate 20, the fixed plate 20 is connected with two springs 21 at one side, one end of the spring 21 abutting against one side in the collecting barrel 17, the fixed plate 20 is fixed with a guide rod 18 at one side, one end of the guide rod 18 penetrating through the collecting barrel 17 and extending to one side of the collecting barrel 17, the spring 21 and the guide rod 18 play a role of buffering and guiding, so as to ensure the stability of the movement of the filtering barrel 15; One side of the collecting barrel 17 is hingedly connected with a connecting cover 19, one side of the filtering box is hingedly connected with a first cover 2, the first cover 2 corresponding to the connecting cover 19, the connecting cover 19 is hingedly connected at one side of the collecting barrel 17, and the first cover 2 is hingedly connected at one side of the filtering box, so that the filtering barrel 15 is convenient to operate and maintain; The stirring device comprises a first driving motor 1 fixed at the upper end of the first fixing frame 3, a stirring rod 12 connected at the output shaft end of the first driving motor 1, the lower end of the stirring rod 12 extending into the filtering barrel 15, a plurality of rectangular stirring blades 13 and spiral stirring blades 14 fixed at the stirring rod 12 at equal intervals, after the first driving motor 1 is started, the stirring rod 12 is driven to rotate, the rectangular stirring blades 13 and the spiral stirring blades 14 stir the tissues in the filtering barrel 15, so that the tissues are fully mixed, and subsequent processing is facilitated; The rotating device comprises a second driving motor 9 fixed at the upper end of the third fixing frame 11, a connecting rod 22 connected at the lower end of the output shaft of the second driving motor 9, a connecting head 23 fixed at the lower end of the connecting rod 22, a circular truncated cone-shaped bearing barrel 24 screwed at the lower end of the connecting head 23, the circular truncated cone-shaped bearing barrel 24 being driven to rotate through the connecting rod 22, so that blood and other samples can be centrifuged and separated; The third fixing frame 11 is provided with a dispersion box, the dispersion box is hingedly connected with a third cover 10 at one side, the second fixing frame 7 is provided with a grinding device 6 at the upper end, the grinding device 6 is provided with a second cover 8, and the grinding device 6 is provided with a second cover 8, so as to grind and process the tissues.

[0027] Reference Figures 8-14A method for regulating FTO based on GLP-1 experimental device, comprising the following steps: S1, animal model establishment, selecting 6-8 week old mice, giving high-fat diet for 12 weeks, establishing an atherosclerosis model; S2, grouping and intervention, high-fat diet group for 16 weeks, GLP-1 group for 12 weeks, GLP-1 for 2.2nmol / (kg·d) intraperitoneal injection for 4 weeks, GLP-1+GLP-1 inhibitor group for 12 weeks, GLP-1 for 2.2nmol / (kg·d)+GLP-1 inhibitor for 22nmol / (kg·d) intraperitoneal injection for 4 weeks; S3, killing mice, taking aortic root tissue, heart, liver and blood, putting the tissue into a filter bucket for treatment, obtaining the required tissue, grinding the grinding device according to the need, and centrifuging the blood according to the need using a rotating device; S4, index detection, aortic root tissue is subjected to oil red O and HE staining, the proportion of plaque area to aortic intima area is analyzed, liver is subjected to oil red O and HE staining, and lipid distribution is observed, animal tissue is ground, protein and RNA are extracted, Western detection is carried out on the expression of FTO, UCP2 and other related indexes in each group, and PCR is used to determine the FTO and UCP2 mRNA levels in the tissue.

[0028] The operation process of the present application is: 1, experimental device preparation Device structure building: two I-shaped steel are taken as the basis, and a first fixing frame, a second fixing frame and a third fixing frame are fixed on the upper end at equal intervals. A filter box and a stirring device are installed on the first fixing frame, a protection box is arranged on one side of the filter box, and a pushing mechanism is installed inside. A rotating device and a dispersion box are installed on the third fixing frame. A grinding device is installed on the second fixing frame.

[0029] Part installation connection: the filter bucket is placed in the collection bucket and connected with the pushing mechanism through the pull rod; the stirring rod extends into the filter bucket; the connecting head of the rotating device is screwed with the circular table-shaped bearing bucket. At the same time, various covers are installed to facilitate operation and maintenance.

[0030] 2, animal experiment Animal model establishment: 6-8 week old mice are selected, and high-fat diet is given for 12 weeks to establish an atherosclerosis model.

[0031] Grouping and intervention: the mice were divided into high-fat diet group, GLP-1 group and GLP-1 + inhibitor group. The high-fat diet group was continuously fed for 16 weeks; the GLP-1 group was fed for 12 weeks, and then GLP-1 2.2 nmol / (kg·d) was injected intraperitoneally for 4 weeks; the GLP-1 + inhibitor group was fed for 12 weeks, and then GLP-1 2.2 nmol / (kg·d) + Exendin (inhibitor) 22 nmol / (kg·d) was injected intraperitoneally for 4 weeks.

[0032] Index detection: the mice were sacrificed, and the aortic root tissue, heart, liver and blood were taken. The tissue was placed in a filter bucket for processing, stirred by a stirring device, and moved by a pushing mechanism to complete filtering and other operations. According to the needs, the tissue was ground using a grinding device, and the blood was centrifuged using a rotating device. Then, the aortic root tissue and liver were stained with oil red O and HE, and the plaque area and lipid distribution were analyzed. After the animal tissue was ground, the protein was extracted, and the expression levels of FTO, UCP2 and other related indicators in each group were detected by Western blotting. The FTO and UCP2 mRNA levels in the tissue were determined by PCR.

[0033] 3. Cell experiment Preparation before experiment: HCAEC (human coronary artery endothelial cells) and ECM endothelial cell culture medium were purchased, and HCAEC was stimulated with 0.1 mg / L LPS to establish an in vitro endothelial cell inflammatory injury model.

[0034] Experimental grouping and intervention: the cells were divided into blank control group (HCAEC + LPS), different concentrations of GLP-1 intervention group (0.5; 1.5; 3; 5; 10 nmol / l) and GLP-1 + inhibitor group (the specific concentration was determined according to the results of the pre-experiment).

[0035] Index detection: PCR was used to determine the FTO and UCP2 mRNA levels in each group of cells, Western blotting was used to determine the expression levels of FTO, UCP2 and other related indicators in each group of cells, ELISA was used to measure the contents of IL-1, CRP and ICAM-1 in the supernatant, and the mRNA m6A quantitative detection kit was used for detection.

[0036] The above is only a preferred specific embodiment of the present application, but the protection scope of the present application is not limited thereto, and any person skilled in the art can make equivalent replacement or change according to the technical solution and inventive concept of the present application within the technical range disclosed by the present application, which should be covered within the protection scope of the present application.

Claims

1. A GLP-1 based FTO experimental setup comprising two I-beams (5), characterized in that, The upper ends of the two I-shaped steel (5) are fixed with the first fixing frame (3), the second fixing frame (7) and the third fixing frame (11), the first fixing frame (3) is provided with the filter box, one side of the filter box is fixed with the protection box (4), the protection box (4) is provided with the pushing mechanism, the filter box is fixed with the collecting barrel (17), the collecting barrel (17) is provided with the filter barrel (15), the pushing mechanism is connected with the filter barrel (15), the upper end of the first fixing frame (3) is provided with the stirring device, the stirring device corresponds with the filter barrel (15), the third fixing frame (11) is provided with the rotating equipment, the rotating equipment is provided with the circular truncated cone bearing barrel (24), the upper end of the second fixing frame (7) is provided with the grinding device (6).

2. The FTO experimental device based on GLP-1 regulation according to claim 1, characterized in that: The pushing mechanism comprises a mounting seat (26) fixed in one side of the protection box (4), a third driving motor (25) mounted on the mounting seat (26), a rotating rod (27) connected to the output shaft of the third driving motor (25), a pull rod (28) rotatably connected to one end of the rotating rod (27), a moving block (30) rotatably connected to one end of the pull rod (28), the moving block (30) is slidably connected to the guide rail (29) at the lower end, the bottom of the protection box (4) is fixed with the guide rail (29), one side of the moving block (30) is fixed with a pull rod (16), one end of the pull rod (16) penetrates the side wall of the protection box (4) and the collecting barrel (17) and is rotatably connected to one side of the filter barrel (15).

3. The FTO experimental device based on GLP-1 regulation according to claim 1, characterized in that: The other side of the filter barrel (15) is fixed with a fixed plate (20), the fixed plate (20) is connected with two springs (21) on one side, one end of the spring (21) abuts against one side in the collecting barrel (17), the fixed plate (20) is fixed with a guide rod (18) on one side, one end of the guide rod (18) penetrates the collecting barrel (17) and extends to one side of the collecting barrel (17).

4. The FTO experimental device based on GLP-1 regulation according to claim 1, characterized in that: One side of the collecting barrel (17) is hingedly connected with a connecting cover (19), one side of the filter box is hingedly connected with a first cover (2), the first cover (2) corresponds with the connecting cover (19).

5. The FTO experimental device based on GLP-1 regulation according to claim 1, characterized in that: The stirring device comprises a first driving motor (1) fixed on the upper end of the first fixing frame (3), a stirring rod (12) connected to the output shaft of the first driving motor (1), the lower end of the stirring rod (12) extends into the filter barrel (15), a plurality of rectangular stirring blades (13) and spiral stirring blades (14) are fixed on the stirring rod (12) at equal intervals.

6. The FTO experimental device based on GLP-1 regulation according to claim 1, characterized in that: The rotating equipment comprises a second driving motor (9) fixed on the upper end of the third fixing frame (11), a connecting rod (22) connected to the lower end of the output shaft of the second driving motor (9), a connecting head (23) fixed on the lower end of the connecting rod (22), and a circular truncated cone bearing barrel (24) screwed on the lower end of the connecting head (23).

7. The FTO experimental device based on GLP-1 regulation according to claim 1, characterized in that: The third fixing frame (11) is provided with a dispersion box, one side of the dispersion box is hingedly connected with a third cover (10).

8. The FTO experimental device based on GLP-1 regulation according to claim 1, characterized in that: The upper end of the second fixing frame (7) is provided with a grinding device (6), and the grinding device (6) is provided with a second cover (8).

9. A method of modulating an FTO experimental setup based on GLP-1, characterized in that, The method comprises the following steps: S1, animal model establishment, 6-8 weeks old mice are selected, high-fat diet is given for feeding for 12 weeks, and an atherosclerosis model is established; S2, grouping and intervention are performed, the high-fat diet group is fed for 16 weeks, the GLP-1 group is fed for 12 weeks, then GLP-1 is given for 2.2 nmol / (kg·d) intraperitoneal injection for 4 weeks, and the GLP-1+GLP-1 inhibitor group is fed for 12 weeks, then GLP-1 is given for 2.2 nmol / (kg·d)+GLP-1 inhibitor 22 nmol / (kg·d) intraperitoneal injection for 4 weeks; S3, the mice are killed, the aortic root tissue, heart, liver and blood are taken, the tissue is placed in a filter bucket for treatment, the required tissue is obtained, the grinding device is ground according to the need, and the blood is centrifuged by using a rotating device according to the need; S4, index detection, the aortic root tissue is subjected to oil red O and HE staining, the proportion of the plaque area to the aortic intima area is analyzed, the liver is subjected to oil red O and HE staining, the lipid distribution is observed, the protein and RNA are extracted after the animal tissue is ground, the expression amounts of FTO, UCP2 and other related indexes in each group are detected by Western, and the FTO and UCP2 mRNA levels in the tissue are determined by PCR.

Images